January 19, 2023
The Japanese health ministry will report plans to approve label expansions for Bayer Yakuhin’s Nubeqa (darolutamide), AbbVie’s Rinvoq (upadacitinib), and Janssen Pharmaceutical’s Imbruvica (ibrutinib) at an advisory panel meeting on February 1. Nubeqa, an oral androgen receptor inhibitor, is expected...read more